Veterans Health Administration Novel Therapeutics Preparedness Act
- Bill Number
- S. 4220
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Armed Forces and National Security
- Status
- Introduced
- Latest Action
- 2026-04-29: Committee on Veterans' Affairs. Hearings held.
- Last Updated
- 2026-04-30T11:03:21Z
AI-Generated Summary
Purpose
The Veterans Health Administration Novel Therapeutics Preparedness Act (S. 4220) aims to prepare the Department of Veterans Affairs (VA) for emerging medical treatments, such as psychedelic-assisted therapies, by creating a centralized office to evaluate, research, and implement these therapies safely and effectively for veterans' mental health conditions like post-traumatic stress disorder (PTSD) and depression.
Key Provisions
- Office of Novel Therapeutics: Establishes this office within the Veterans Health Administration (VHA), led by a Director appointed by the Under Secretary for Health. The office develops national policies, clinical standards, training programs, patient eligibility guidelines, and implementation plans for "emerging therapeutic interventions" (treatments under FDA review).
- Clinical Implementation Program: Tests new therapies in real-world VA settings to assess effectiveness, safety, and scalability, prioritizing conditions like PTSD, depression, substance use disorders, traumatic brain injury, and chronic pain.
- Centers of Excellence: Designates VA medical centers to lead research, training, and rollout of novel therapies, providing best practices and technical support network-wide.
- Veteran Advisory Committee: Includes veterans, caregivers, experts, and academics to advise on safety, consent, access, and patient-centered care.
- Interagency Coordination: Requires collaboration with FDA, HHS, CMS, DoD, and DEA on regulations, billing, drug scheduling, and data sharing.
- Annual Reports to Congress: Covers research, outcomes, safety, workforce readiness, barriers, and recommendations.
- National Strategy: VA must submit a preparedness plan within 180 days, addressing workforce, facilities, timelines, and barriers.
Significant Changes to Existing Law
- Amends title 38, United States Code (governing VA benefits and services) by adding a new Subchapter VI to Chapter 73, introducing sections 7391–7397 with definitions, office structure, programs, and reporting requirements.
- No prior centralized VA office existed for novel therapeutics, shifting from decentralized approaches to coordinated, evidence-based planning to avoid delays or risks post-FDA approval.
Potential Impacts
- Government Agencies: Enhances VA's readiness for FDA-approved therapies, requiring infrastructure upgrades, training investments, and interagency data sharing; may increase DoD and HHS coordination for veteran care transitions.
- Citizens (Veterans): Improves access to innovative mental health treatments through standardized care models, peer support, and integration services, potentially reducing treatment gaps for PTSD and related conditions.
- International Relations: None directly addressed.
Main Stakeholders Affected
- Veterans: Primary beneficiaries, especially those with mental health challenges, through better treatment options and veteran input via advisory committee.
- VA Staff: Clinicians, researchers, and peer specialists gain training, credentialing, and protected time for new therapies.
- Federal Agencies: FDA, HHS, CMS, DoD, and DEA for regulatory and data support.
- Medical Centers and Affiliates: Designated centers and academic partners lead implementation and research.
Notable Legal, Constitutional, or Political Implications
- Legal: Mandates evidence-based standards and patient safety protocols, distinguishing research from clinical care to avoid overly restrictive rules; requires congressional oversight via reports.
- Constitutional: Aligns with Congress's authority over VA operations and spending; emphasizes patient consent and safety, respecting due process.
- Political: Bipartisan sponsorship (Sens. Sheehy, Gallego, Duckworth, Boozman) signals broad support for veteran mental health innovation without altering drug laws directly.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Sen. Gallego, Ruben [D-AZ], Sen. Duckworth, Tammy [D-IL], Sen. Boozman, John [R-AR]
Recent Actions
- 2026-04-29: Committee on Veterans' Affairs. Hearings held.
- 2026-03-26: Read twice and referred to the Committee on Veterans' Affairs.
- 2026-03-26: Introduced in Senate
Bill Versions
- Veterans Health Administration Novel Therapeutics Preparedness Act — issued 2026-03-26 — PDF (13 pages)